Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Cash & Equivalents (2016 - 2025)

Phibro Animal Health (PAHC) has 13 years of Cash & Equivalents data on record, last reported at $55.5 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 17.28% year-over-year to $55.5 million; the TTM value through Dec 2025 reached $55.5 million, down 17.28%, while the annual FY2025 figure was $68.0 million, 3.65% down from the prior year.
  • Cash & Equivalents reached $55.5 million in Q4 2025 per PAHC's latest filing, down from $72.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $76.3 million in Q3 2022 and bottomed at $33.0 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $57.2 million, with a median of $57.9 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: crashed 51.81% in 2023, then surged 103.44% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $63.4 million in 2021, then increased by 7.95% to $68.4 million in 2022, then plummeted by 51.81% to $33.0 million in 2023, then soared by 103.44% to $67.1 million in 2024, then decreased by 17.28% to $55.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $55.5 million in Q4 2025, $72.8 million in Q3 2025, and $68.0 million in Q2 2025.